Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Pathway of Low Anterior Resection Syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancer

Croft, Julie, Farrow, Emily, Coxon-Meggy, Alexandra Harriet, Gordon, Katie, Corrigan, Neil, Mather, Hannah, Stocken, Deborah D, Dale, Megan, Chong, Huey Yi, White, Judith, Knight, Laura, Meggy, Alun, Lloydwin, Christina, Tan, Betty, Douglas, Ashley, Powell, Ralph, Hepburn, Julie, Jayne, David, Torkington, Jared, Warwick, Andrea, Ng, Kheng-Seong, Wilson, Kate, Knowles, Charles H, Quyn, Aaron and Cornish, Julie ORCID: https://orcid.org/0000-0003-4360-4472 2025. Pathway of Low Anterior Resection Syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancer. BMJ Open 15 (2) , e092612. 10.1136/bmjopen-2024-092612

[thumbnail of e092612.full.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB)

Abstract

Introduction As a result of improving survival rates, the adverse consequences of rectal cancer surgery are becoming increasingly recognised. Low anterior resection syndrome (LARS) is one such consequence and describes a constellation of bowel symptoms after rectal cancer surgery which includes urgency, faecal incontinence, stool clustering and incomplete evacuation. LARS has a significant adverse impact on quality of life (QoL) and symptoms are present in up to 75% of patients in the first year after surgery. Despite this, little is known about the natural history and there is poor evidence to support current treatment options.Methods and analysisThe objectives of POLARiS are to explore the natural history of LARS and to evaluate the clinical and cost-effectiveness of transanal irrigation (TAI) or sacral neuromodulation (SNM) compared with optimised conservative management (OCM) for people with major LARS.POLARiS is a prospective, international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort design, with internal pilot phase, qualitative sub-study, process evaluation and economic evaluation. Approximately 1500 adult participants from UK hospitals and 500 from Australian hospitals who have undergone a high or low anterior resection for colorectal cancer in the last 10 years will be recruited into the cohort. Six-hundred participants from the UK and 200 participants from Australia, with major LARS symptoms, defined as a LARS score of ≥30, will be recruited to the randomised controlled trial (RCT) element. Participants entering the RCT will be randomised between OCM, TAI or SNM, all with equal allocation ratios.Cohort and RCT participants will be followed up for a 24-month period, completing a series of questionnaires measuring LARS symptoms and QoL, as well as clinical review for those in the RCT. A process evaluation, qualitative sub-study and economic evaluation will also be conducted.The primary outcome measure of the POLARiS cohort and RCT is the LARS score up to 24 months post-registration/randomisation. Analyses of the RCT will be conducted on an intention-to-treat basis. Comparative effectiveness analyses for each endpoint will consist of two pairwise treatment comparisons: TAI versus OCM and SNM versus OCM. Secondary outcomes include health-related QoL, adverse events, treatment compliance and cost-effectiveness (up to 24 months post-registration/randomisation).Ethics and disseminationEthical approval has been granted by Wales REC 4 (reference: 23/WA/0171) in the UK and Sydney Local Health District HREC (reference: 2023/ETH00749) in Australia. The results of this trial will be disseminated to participants on request and published on completion of the trial in a peer-reviewed journal and at international conferences.Trial registration numberISRCTN12834598; ACTRN12623001166662.

Item Type: Article
Status: Published
Schools: Medicine
Additional Information: License information from Publisher: LICENSE 1: Title: cc by, Type: cc by
Publisher: BMJ Publishing Group
Date of First Compliant Deposit: 13 February 2025
Date of Acceptance: 29 November 2024
Last Modified: 13 Feb 2025 16:30
URI: https://orca.cardiff.ac.uk/id/eprint/176171

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics